Clinical research
Gestational diabetes mellitus is associated with increased leukocyte peroxisome proliferator-activated receptor γ expression
 
More details
Hide details
 
Submission date: 2013-11-26
 
 
Final revision date: 2014-01-17
 
 
Acceptance date: 2014-03-06
 
 
Online publication date: 2015-01-14
 
 
Publication date: 2015-08-10
 
 
Arch Med Sci 2015;11(4):779–787
 
KEYWORDS
TOPICS
ABSTRACT
Introduction: Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor of the nuclear receptor superfamily that is involved in lipid and carbohydrate metabolism as well as inflammation; thereby it participates in metabolic diseases including diabetes. Although PPARγ expression has been observed in different tissues of diabetic patients, its level in leukocytes from subjects affected by gestational diabetes mellitus (GDM) has not yet been reported. This study aimed to investigate leukocyte PPARG expression in GDM patients at 24–33 weeks of gestation and, in turn, to correlate these alterations with anthropometric and metabolic parameters of patients.
Material and methods: Leukocytes were isolated from the blood of normal glucose tolerant (NGT; n = 34) and GDM (n = 77) pregnant women between 24 and 33 weeks of gestation. Leukocyte PPARG mRNA expression was determined by semi-quantitative polymerase chain reaction. Univariate correlation analysis was performed to investigate associations between PPARG expression and clinical characteristics of patients.
Results: Leukocyte PPARG mRNA level was significantly higher in GDM than NGT women (p < 0.05). In the whole study group, PPARG expression positively correlated with plasma glucose concentrations at 1 h (r = 0.222, p = 0.049) and 2 h (r = 0.315, p = 0.020) of 75 γ oral glucose tolerance test (OGTT), and negatively correlated with plasma HDL cholesterol concentration (r = γ 0.351, p = 0.010).
Conclusions: The correlation between leukocyte PPARG overexpression and hyperglycaemia suggests that PPARG mRNA expression in these cells might be up-regulated in high-glucose conditions in GDM patients at 24–33 weeks of gestation.
eISSN:1896-9151
ISSN:1734-1922